What drugs should not be taken with Dayvigo?

The effects of other drugs on DAYVIGO

Strong, moderate and weak CYP3A inhibitors

Clinical Impact:

Coadministration with strong, moderate, or weak CYP3A inhibitors may increase the AUC and Cmax of lemborexant, thereby increasing the risk of adverse effectsof lemborexant.

Intervention:

Avoid coadministrationof this product with strong or moderate CYP3A inhibitors.

The maximum recommended dose when coadministered with a weak inhibitor of CYP3A is 5 mg.

Example:

Strong CYP3A inhibitors: itraconazole, clarithromycin

Moderate CYP3A inhibitors: fluconazole, verapamil

Weak CYP3A inhibitors: chlorzoxazone, ranitidine

Poor and moderate CYP3A inducers

Clinical Impact:

Coadministration with strong or moderate CYP3A inducers may reduce lemborexant exposure and thus reduce the efficacyof this product.

Intervention:

Avoid coadministrationof this product with strong or moderate CYP3A inducers.

Example:

Strong CYP3A inducers: rifampicin, carbamazepine, St. John's wort

Moderate CYP3A inducers: bosentan, efavirenz, etravirine, modafinil

Alcohol

Clinical Impact:

Concomitant use of alcohol may increase the Cmax and AUC of lemborexant. Evaluated near the tmax of DAYVIGO (2 hours post-dose), coadministration of DAYVIGO with alcohol was found to have numerically greater negative effects on postural stability and memory than alcohol alone.

Intervention:

Avoid alcohol.

How DAYVIGO affects other drugs

CYP2B6 Substrate

Clinical Impact:

Coadministration of DAYVIGO may decrease the AUC of drugs that are CYP2B6 substrates, potentially reducing the efficacyof these coadministered drugs.

Intervention:

Patients receiving DAYVIGO concomitantly with a CYP2B6 substrate should be monitored for adequate clinical response. Consider increasing the dose of the CYP2B6 substrate as needed.

Example:

Bupropion, methadone